rethinkTHC Search
Menu
Study breakdown

Scoping Review Finds Preclinical Promise but Limited Clinical Evidence for Cannabis in Rheumatoid Arthritis

Scoping ReviewPreliminary evidence
The takeaway

Preclinical studies show promising anti-inflammatory and analgesic effects of cannabinoids for rheumatoid diseases, but clinical studies are scarce with mixed results and no recommendations exist.

RA patients, rheumatologists, medical cannabis researchers.

Promising preclinical data but no clinical recommendations for cannabis in RA

What the researchers found

Preclinical studies demonstrated cannabinoids can halt disease progression and relieve pain. Clinical studies are scarce with mixed results. No clinical recommendations exist.

Why it matters

Many patients already use cannabis without clinical guidance. The evidence base is insufficient for practice.

The numbers in context

Preclinical: promising. Clinical: scarce with mixed results. No recommendations. Conditions: RA, OA, fibromyalgia.

How the study worked

Scoping review examining preclinical and clinical data on cannabis for RA, osteoarthritis, and fibromyalgia.

What this study cannot tell us

Heterogeneous studies. Limited clinical data. Variable formulations and dosing.

How to read the evidence

Scoping review limited by scarce and heterogeneous clinical evidence.

When this study was published

Published 2023.

The bigger picture

The disconnect between preclinical promise and clinical reality is a recurring theme across cannabis medicine.

Questions still open

  • What evidence threshold is needed before clinical recommendations?
  • Which cannabinoid formulation shows most promise?

Common questions

Can cannabis help with rheumatoid arthritis?
Lab studies suggest anti-inflammatory and pain-relieving properties, but clinical evidence is scarce with mixed results.
Should RA patients try cannabis?
No established clinical recommendations exist. The evidence is insufficient.

Read the original research

Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions.

Rambam Maimonides medical journal, 14(4)

Citation

Paland, Nicole; Hamza, Haya; Pechkovsky, Antonina; Aswad, Miran; Shagidov, Dayana; Louria-Hayon, Igal. (2023). Cannabis and Rheumatoid Arthritis: A Scoping Review Evaluating the Benefits, Risks, and Future Research Directions.. Rambam Maimonides medical journal, 14(4). https://doi.org/10.5041/RMMJ.10509

Explore the wider topic